DOPATREE
Preview
Open in TheBrain
DOPATREE
PRODUCTS
DRUGS AND BIOLOGICS-ALL (DRUG-DEVICE, BIOLOGIC-DEVICE COMBOS, COMBINATIONS, MEDICINES, THERAPEUTICS)
DRUGS AND BIOLOGICS / RELATED / US
EMA RISK MANAGEMENT PLANS (RMP, EU RMP, EMA RMP)
EMA RISK MANAGEMENT PLANS / RELATED
RISK MINIMIZATION MEASURES (RMM, ADDITIONAL, ARMM, ROUTINE, RRMM)
RISK MINIMIZATION MEASURES / LISTINGS / ROUTINE
Parents
RISK MINIMIZATION MEASURES (RMM, ADDITIONAL, ARMM, ROUTINE, RRMM)
Children
ADJUSTING THE DOSE OR STOPPING THE TREATMENT WHEN ADVERSE EVENTS ARE OBSERVED OR LABORATORY PARAMETERS CHANGE
MONITORING FOR SPECIFIC SIGNS AND SYMPTOMS
MONITORING OF LABORATORY PARAMETERS DURING TREATMENT
PERFORMING A TEST BEFORE START OF TREATMENT
PERFORMING A WASH‐OUT PROCEDURE AFTER TREATMENT INTERRUPTION
PROHIBITING THE USE OF OTHER MEDICINES WHILE TAKING THE PRODUCT
PROVIDING CONTRACEPTION RECOMMENDATIONS
RECOMMENDING LONG‐TERM CLINICAL FOLLOW‐UP TO IDENTIFY DELAYED ADVERSE EVENTS IN EARLY STAGES
TREATING OR PREVENTING THE RISK FACTORS THAT MAY LEAD TO AN ADVERSE EVENT OF THE PRODUCT